JP2016520615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520615A5 JP2016520615A5 JP2016517030A JP2016517030A JP2016520615A5 JP 2016520615 A5 JP2016520615 A5 JP 2016520615A5 JP 2016517030 A JP2016517030 A JP 2016517030A JP 2016517030 A JP2016517030 A JP 2016517030A JP 2016520615 A5 JP2016520615 A5 JP 2016520615A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administration
- disease
- group
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000000589 Interleukin-1 Human genes 0.000 claims description 83
- 108010002352 Interleukin-1 Proteins 0.000 claims description 83
- 201000010099 disease Diseases 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 239000005557 antagonist Substances 0.000 claims description 32
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 28
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 26
- 229940124597 therapeutic agent Drugs 0.000 claims description 26
- 208000024891 symptom Diseases 0.000 claims description 19
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 102000037865 fusion proteins Human genes 0.000 claims description 16
- 230000008021 deposition Effects 0.000 claims description 12
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 9
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 9
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 8
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 8
- 102000044594 Interleukin-1 Receptor Accessory Human genes 0.000 claims description 8
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 8
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 8
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 8
- 229930195712 glutamate Natural products 0.000 claims description 8
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical group C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 8
- 208000028698 Cognitive impairment Diseases 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 6
- 238000001361 intraarterial administration Methods 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 238000007913 intrathecal administration Methods 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 238000007914 intraventricular administration Methods 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 102000029749 Microtubule Human genes 0.000 claims description 5
- 108091022875 Microtubule Proteins 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 210000004688 microtubule Anatomy 0.000 claims description 5
- 239000003607 modifier Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 4
- 208000000044 Amnesia Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 4
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 4
- 206010022998 Irritability Diseases 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 206010027951 Mood swings Diseases 0.000 claims description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 4
- 229960004238 anakinra Drugs 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 229940039856 aricept Drugs 0.000 claims description 4
- 230000006399 behavior Effects 0.000 claims description 4
- 210000005013 brain tissue Anatomy 0.000 claims description 4
- 229960001838 canakinumab Drugs 0.000 claims description 4
- 229960003530 donepezil Drugs 0.000 claims description 4
- 229930013356 epothilone Natural products 0.000 claims description 4
- 150000003883 epothilone derivatives Chemical group 0.000 claims description 4
- 229960003980 galantamine Drugs 0.000 claims description 4
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 229960004640 memantine Drugs 0.000 claims description 4
- 230000006984 memory degeneration Effects 0.000 claims description 4
- 208000023060 memory loss Diseases 0.000 claims description 4
- 229940033872 namenda Drugs 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 229940051845 razadyne Drugs 0.000 claims description 4
- 229960004323 rivastigmine tartrate Drugs 0.000 claims description 4
- 229950007874 solanezumab Drugs 0.000 claims description 4
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 229940119336 Microtubule stabilizer Drugs 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 230000003920 cognitive function Effects 0.000 claims description 3
- 229950002508 gantenerumab Drugs 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 52
- 210000002784 stomach Anatomy 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 52
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361829713P | 2013-05-31 | 2013-05-31 | |
| US61/829,713 | 2013-05-31 | ||
| PCT/US2014/040160 WO2014194166A1 (en) | 2013-05-31 | 2014-05-30 | Methods of using il-1 antagonists to treat alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076729A Division JP2018111723A (ja) | 2013-05-31 | 2018-04-12 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520615A JP2016520615A (ja) | 2016-07-14 |
| JP2016520615A5 true JP2016520615A5 (enExample) | 2017-05-18 |
Family
ID=51023151
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517030A Pending JP2016520615A (ja) | 2013-05-31 | 2014-05-30 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
| JP2018076729A Pending JP2018111723A (ja) | 2013-05-31 | 2018-04-12 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076729A Pending JP2018111723A (ja) | 2013-05-31 | 2018-04-12 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160120941A1 (enExample) |
| EP (1) | EP3003356B1 (enExample) |
| JP (2) | JP2016520615A (enExample) |
| AU (1) | AU2014274044B2 (enExample) |
| CA (1) | CA2911547A1 (enExample) |
| WO (1) | WO2014194166A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107847504A (zh) * | 2015-05-18 | 2018-03-27 | 斯奈普泰克发展有限责任公司 | 淀粉状蛋白β的加兰他敏清除 |
| KR20190072521A (ko) * | 2016-09-12 | 2019-06-25 | 스티븐 호프만 | 치매를 치료하기 위한 조성물 |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| CA3087865A1 (en) * | 2018-01-31 | 2019-08-08 | Olatec Therapeutics Llc | Method for preventing or treating alzheimer's disease |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN111956933B (zh) * | 2020-08-27 | 2022-05-03 | 北京理工大学 | 一种阿尔兹海默病神经反馈康复系统 |
| WO2022167916A1 (en) * | 2021-02-03 | 2022-08-11 | Novartis Ag | Use of il-1b binding antibodies for treating neuroinflammatory disorders |
| KR20230109107A (ko) * | 2022-01-10 | 2023-07-19 | (주)지아이이노베이션 | 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965421A (en) * | 1997-11-26 | 1999-10-12 | Human Genome Sciences, Inc. | Human IRAK-2 |
| US6927044B2 (en) * | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7629311B2 (en) * | 1999-02-24 | 2009-12-08 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
| US8119127B2 (en) * | 1999-02-24 | 2012-02-21 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| US20020131954A1 (en) * | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| WO2002103031A2 (en) * | 2001-06-15 | 2002-12-27 | Interleukin Genetics, Inc. | Methods for detecting and treating the early onset of aging-related conditions |
| US7790867B2 (en) * | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
| US20050129685A1 (en) * | 2003-09-18 | 2005-06-16 | Jingtai Cao | Use of IL-1 blockers to prevent corneal inflammation and neovascularization |
| US8618054B2 (en) * | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| CA2568352C (en) * | 2004-06-04 | 2011-09-13 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat autoinflammatory disease |
| PE20061329A1 (es) * | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
| EP2314623B1 (en) * | 2005-06-21 | 2012-07-04 | XOMA Technology Ltd. | IL-1beta binding antibodies and fragments thereof |
| US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
| JP2012501184A (ja) * | 2008-08-28 | 2012-01-19 | ワイス・エルエルシー | 自己免疫疾患におけるｉｌ−２２、ｉｌ−１７、およびｉｌ−１ファミリーのサイトカインの使用 |
| CA2832672A1 (en) * | 2010-04-16 | 2011-10-20 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
| SG187231A1 (en) * | 2010-07-29 | 2013-02-28 | Eleven Biotherapeutics Inc | Chimeric il-1 receptor type i agonists and antagonists |
| JP6120782B2 (ja) * | 2011-03-14 | 2017-04-26 | フロゴ エーピーエス | インターロイキン−１受容体のアンタゴニスト |
-
2014
- 2014-05-30 JP JP2016517030A patent/JP2016520615A/ja active Pending
- 2014-05-30 CA CA2911547A patent/CA2911547A1/en not_active Abandoned
- 2014-05-30 EP EP14733888.3A patent/EP3003356B1/en active Active
- 2014-05-30 US US14/893,932 patent/US20160120941A1/en not_active Abandoned
- 2014-05-30 WO PCT/US2014/040160 patent/WO2014194166A1/en not_active Ceased
- 2014-05-30 AU AU2014274044A patent/AU2014274044B2/en not_active Ceased
-
2018
- 2018-04-12 JP JP2018076729A patent/JP2018111723A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520615A5 (enExample) | ||
| Ryu et al. | Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer’s disease | |
| Cao et al. | Postoperative cognitive deficits and neuroinflammation in the hippocampus triggered by surgical trauma are exacerbated in aged rats | |
| Okuma et al. | Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1–RAGE interaction | |
| Sicotte et al. | Immunization with myelin or recombinant Nogo-66/MAG in alum promotes axon regeneration and sprouting after corticospinal tract lesions in the spinal cord | |
| JP2017534638A5 (enExample) | ||
| JP2011507891A5 (enExample) | ||
| JP2017158561A5 (enExample) | ||
| HRP20210559T1 (hr) | Pripravci i postupci inhibiranja masp-1 i/ili masp-2 i/ili masp-3 za liječenje raznih bolesti i poremećaja | |
| JP2017042172A5 (enExample) | ||
| Ma et al. | Ribonuclease attenuates hepatic ischemia reperfusion induced cognitive impairment through the inhibition of inflammatory cytokines in aged mice | |
| AU2016215035A1 (en) | Compounds and uses in treatment of senescence-associated conditions | |
| Ahmed et al. | Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals—A randomized double-blind pre-clinical study | |
| JP2018511327A5 (enExample) | ||
| Goel et al. | Hypertension exacerbates predisposition to neurodegeneration and memory impairment in the presence of a neuroinflammatory stimulus: protection by angiotensin converting enzyme inhibition | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2020521797A5 (enExample) | ||
| JP2013533287A5 (enExample) | ||
| JP2019518779A5 (enExample) | ||
| WO2017072335A1 (en) | Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease | |
| JP2018529661A5 (enExample) | ||
| JP2018516944A5 (enExample) | ||
| JP2017518316A5 (enExample) | ||
| JP2018534259A5 (enExample) | ||
| JP2018530574A5 (enExample) |